Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A pharmaceutical composition comprising HS024 as an active ingredient in an amount effective to protect neuronal cell and to treat or prevent human or mammal suffering from brain diseases such as brain stroke and degenerative brain diseases, together More
“Iterative Stochastic Elimination†(ISE) that can lead to extremely fast and reliable discovery of drug candidates and shorten the time for preclinical hit and lead discovery from 3-4 years to about a tenth of that time. Keywords: Alzheimer Top 30 More
Your selection
Browse By
- Therapeutic target
- Age-related disorders (other)
- Amyotrophic lateral sclerosis
- CNS (other)
- Neurodegenerative disorders
- Neurological
- Pain
- Psychiatric
- Subarachnoid hemorrhage
- Traumatic brain injury
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us